Loading patent…
AssigneeThe University of Queensland
InventorsMathias FRANCOIS, Johannes ZUEGG, Jeroen OVERMAN, Sreeman Kumar MAMIDYALA, Angela Aguslyarti SALIM, Frank Roger FONTAINE, Matthew Allister COOPER, Robert John CAPON, Avril Alexis Barbara ROBERTSON
Estimating the term…
Disclosed are compounds of a formula provided herein that show efficacy in the inhibition of SOX18 protein activity, and in particular with respect to the ability of SOX18 to bind DNA and/or particular protein partners. Further, methods of treating angiogenesis- and/or lymphangiogenesis-related diseases, disorders or conditions, such as cancer metastasis and vascular cancers, are provided herein.
A compound of formula (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof:
The compound of any one of the preceding claims, wherein R4 is selected from the group consisting of H, OH, OMe, Cl and Me.
The compound of any one of the preceding claims, wherein R5 is selected from the group consisting of H, OH and OMe.
The compound of any one of the preceding claims, wherein R4 and R5 are H.
The compound of any one of the preceding claims, wherein L is a linker selected from C2-C6 alkyl, C2-C6 alkenyl and C2-C6 alkoxyalkyl.
The compound of any one of the preceding claims, wherein R3 is selected from the group consisting of:
The compound of any one of the preceding claims, wherein the compound is selected from the group consisting of:
The compound of any one of the preceding claims, wherein the SOX18 activity includes contacting and/or binding to a DNA sequence and/or a protein.
A pharmaceutical composition comprising a compound of any one of the preceding claims, or a pharmaceutically acceptable salt, solvate or prodrug thereof, and a pharmaceutically acceptable carrier, diluent and/or excipient.
Dependencies are inferred from the claim text.